LigaChem Biosciences Inc (141080) · Earnings Release

SK Biopharmaceuticals Co Ltd (326030) · Other

SK Biopharmaceuticals is scheduled to be removed from the MSCI Korea Index effective at the close of May 29, 2026, following an announcement on May 12, 2026, which may lead to passive fund outflows, scheduled. Medium impact estimated due to expected passive fund outflows.

5/29/2026, 12:00:00 AM

Voronoi Inc (310210) · Other

Corporate briefing (IR) for domestic and international institutional investors to explain company status scheduled; 1% price impact as IR sessions typically have limited immediate market reaction analysts estimated.

5/18/2026, 12:00:00 AM

OliX Pharmaceuticals Inc (226950) · Other

CEO Dong Ki Lee is scheduled to present research on the company's RNAi platform for ophthalmic diseases at the TIDES USA 2026 conference on May 14, 2026; a 5% price impact is estimated due to potential clinical data updates, scheduled.

5/14/2026, 12:00:00 AM

HK inno N Corporation (195940) · Other

Announced on May 13, 2026, that its blockbuster drug 'K-CAB' became the top-prescribed drug in Korea for April 2026, with monthly outpatient prescription sales of KRW 20.8 billion.

5/13/2026, 12:00:00 AM

Daewoong Pharmaceutical Co Ltd (069620) · Earnings Release

Daewoong Pharmaceutical announced its Q1 2026 earnings on May 12, 2026. On a separate basis, revenue was KRW 335.7 billion (+6.2% YoY) while operating profit was KRW 27.4 billion (-34.7% YoY).

5/12/2026, 12:00:00 AM

Daewoong Pharmaceutical Co Ltd (069620) · Other

On May 12, 2026, the company announced a license-in and co-development agreement with Innovo Therapeutics for the IBD drug candidate 'INV-008'. The total deal size is up to KRW 662.5 billion, including an upfront payment of KRW 6.5 billion.

5/12/2026, 12:00:00 AM